Lars Romer Krusell
Overview
Explore the profile of Lars Romer Krusell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westra J, Tu S, Winther S, Nissen L, Vestergaard M, Andersen B, et al.
Circ Cardiovasc Imaging
. 2018 Mar;
11(3):e007107.
PMID: 29555835
Background: Quantitative flow ratio (QFR) is a novel diagnostic modality for functional testing of coronary artery stenosis without the use of pressure wires and induction of hyperemia. QFR is based...
2.
Nielsen-Kudsk J, Andersen A, Therkelsen C, Christensen E, Jensen K, Krusell L, et al.
EuroIntervention
. 2017 Jul;
13(9):e1020-e1025.
PMID: 28691908
Aims: Transcatheter valve-in-valve (VIV) implantation is usually discouraged in small surgical tissue valves. We report our first ten cases of fracturing small dysfunctional Mitroflow bioprostheses by high-pressure balloon dilatation to...
3.
Jensen J, Botker H, Mathiassen O, Grove E, Ovrehus K, Pedersen K, et al.
Eur Heart J Cardiovasc Imaging
. 2017 Apr;
19(4):405-414.
PMID: 28444153
Aims: To assess the use of downstream coronary angiography (ICA) and short-term safety of frontline coronary CT angiography (CTA) with selective CT-derived fractional flow reserve (FFRCT) testing in stable patients...
4.
Jensen L, Thayssen P, Maeng M, Ravkilde J, Krusell L, Raungaard B, et al.
Circ Cardiovasc Interv
. 2016 Jul;
9(7).
PMID: 27412869
Background: Coronary drug-eluting stents with biodegradable polymers have been designed to improve safety and efficacy. Methods And Results: The Scandinavian Organization for Randomized Trials With Clinical Outcome (SORT OUT) VII...
5.
Thim T, Egholm G, Olesen K, Kaltoft A, Terkelsen C, Krusell L, et al.
Open Heart
. 2016 Jul;
3(1):e000427.
PMID: 27403331
Objective: It remains unknown whether complete revascularisation is optimally performed in patients with ST segment elevation myocardial infarction (STEMI) during the index or at staged procedures. The aims of this...
6.
Nielsen-Kudsk J, Christiansen E, Terkelsen C, Norgaard B, Jensen K, Krusell L, et al.
Circ Cardiovasc Interv
. 2015 Jul;
8(8):e002667.
PMID: 26208503
No abstract available.
7.
Maeng M, Baranauskas A, Christiansen E, Kaltoft A, Holm N, Krusell L, et al.
Catheter Cardiovasc Interv
. 2015 Feb;
86(7):1161-7.
PMID: 25640050
Objective: We aimed to compare angiographic and clinical outcomes after the implantation of everolimus-eluting (EES) and sirolimus-eluting (SES) stents in patients with diabetes. Background: There are limited data on long-term...
8.
Raungaard B, Jensen L, Tilsted H, Christiansen E, Maeng M, Terkelsen C, et al.
Lancet
. 2015 Jan;
385(9977):1527-35.
PMID: 25601789
Background: New-generation drug-eluting coronary stents have reduced the risk of coronary events, especially in patients with complex disease or lesions. To what extent different stent platforms, polymers, and antiproliferative drugs...
9.
Hebsgaard L, Nielsen T, Tu S, Krusell L, Maeng M, Veien K, et al.
Int J Cardiol
. 2015 Jan;
182:272-8.
PMID: 25585362
Background: Intracoronary imaging provides accurate lesion delineation and precise measurements for sizing and positioning of coronary stents. During percutaneous coronary intervention (PCI), it may be challenging to identify corresponding segments...
10.
Thim T, Johansen M, Chisholm G, Schmidt M, Kaltoft A, Sorensen H, et al.
BMC Cardiovasc Disord
. 2014 Aug;
14:100.
PMID: 25125079
Background: The impact of adherence to the recommended duration of dual antiplatelet therapy after first generation drug-eluting stent implantation is difficult to assess in real-world settings and limited data are...